The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Angiotensin inhibition in renovascular disease: A population-based cohort study
Abstract
Background Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers effectively reduce blood pressure in patients with renovascular disease (RVD); yet, randomized cardiovascular prevention trials of these drugs typically exclude individuals with this condition.Patients and methods We studied the association of renin-angiotensin system inhibition with prognosis in a population-based cohort comprising 3,570 patients with RVD in Ontario, Canada; slightly more than half (n = 1,857, 53%) were prescribed angiotensin inhibitors. The primary outcome was the composite of death, myocardial infarction, or stroke. Secondary outcomes included individual cardiovascular and renal events.Results Patients receiving angiotensin inhibitors had a significantly lower risk for the primary outcome during follow-up (10.0 vs 13.0 events per 100 patient-years at risk, multivariable adjusted hazard ratio [HR] 0.70, 95% CI 0.59-0.82). In addition, hospitalization for congestive heart failure (HR 0.69, 95% CI 0.53-0.90), chronic dialysis initiation (HR 0.62, 95% CI 0.42-0.92), and mortality (HR 0.56, 95% CI 0.47-0.68) was lower in treated patients. Conversely, patients receiving angiotensin inhibitors were significantly more likely to be hospitalized for acute renal failure during follow-up (HR 1.87, 95% CI 1.05-3.33; 1.2 vs 0.6 events per 100 patient-years at risk).Conclusions These data emphasize the high vascular risk of RVD and suggest that angiotensin inhibitors may improve prognosis in this setting at the expense of acute renal toxicity. If the latter are selected in the management of RVD, renal function parameters should be assiduously followed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Large data registries indicate that ACE inhibitor or ARB treatment in patients with identified renal artery stenosis confers a long-term mortality benefit.317”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [317]
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Des Jarlais, D. C., Lyles, C., Crepaz, N., & the TREND Group (2004) · American Journal of Public Health · doi:10.2105/ajph.94.3.361 · Cited by 2,817
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., de Zeeuw, D., Shahinfar, S., Toto, R. D., Levey, A. S., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-4-200308190-00006 · Cited by 1,149
Safian, R. D., & Textor, S. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102083440607 · Cited by 1,102
Casas, J. P., Chua, W., Loukogeorgakis, S., Vallance, P. J., Smeeth, L. L., Hingorani, A. D., & MacAllister, R. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67814-2 · Cited by 738
Immortal time bias in observational studies of drug effects
Suissa, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1357 · Cited by 593
Austin, P. C., Daly, P. A., & Tu, J. V. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123839 · Cited by 524
Prevalence of renovascular disease in the elderly: A population-based study
Hansen, K. J., Edwards, M. S., Craven, T. E., Cherr, G. S., Jackson, S., Appel, R. G., Burke, G. L., & Dean, R. H. (2002) · Journal of Vascular Surgery · doi:10.1067/mva.2002.127351 · Cited by 496
(2003) · PubMed · Cited by 490
Research works printed but not linked: 1
- Lindsay, 2005, Validation of administrative databases using a registry data source: implications for research on quality of stroke care, Stroke, 36, 477
Cited by
Sorted by citations
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
ESC Guidelines on the diagnosis and treatment of peripheral artery diseases
Endorsed by: the European Stroke Organisation (ESO), Authors/Task Force Members, Tendera, M., Aboyans, V., Bartelink, M.-L., Baumgartner, I., Clément, D., Collet, J.-P., Cremonesi, A., De Carlo, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr211 · Cited by 1,506
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixidó‐Turà, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., Backer, J. F. A. D., Déglise, S., Corte, A. D., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 1,313
Metadata
- Authors
- Hackam, D. G., Duong-Hua, M. L., Mamdani, M., Li, P., Tobe, S. W., Spence, J. D., & Garg, A. X.
- Affiliations
- Western University (CA)
- Institute for Clinical Evaluative Sciences (CA)
- University of Toronto (CA)
- Corresponding author
- Hackam, Daniel G.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 156
- Issue
- 3
- Pages
- 549-555
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W1976834810
- Cited by
- 143
- References
- 57
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 7 · 2018: 12 · 2017: 6 · 2016: 12 · 2015: 8 · 2014: 16 · 2013: 9 · 2012: 13
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- renovascular disease, ACE inhibitors, angiotensin receptor blockers, renin-angiotensin system blockade, cardiovascular outcomes, acute kidney injury, congestive heart failure, dialysis initiation, mortality, stroke, myocardial infarction, renal function monitoring
- MeSH terms
- Aged, Aged, 80 and over, Angiotensins, Cardiovascular Diseases, Female, Follow-Up Studies, Heart Failure, Renal Dialysis, Hormone Antagonists, Hospitalization, Humans, Kidney, Kidney Diseases, Male, Myocardial Infarction, Renin-Angiotensin System, Vascular Diseases, Cohort Studies, Proportional Hazards Models, Risk Assessment, Stroke, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
